Header Logo

Philip Bonomi

Concepts (526)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Lung Neoplasms
150
2021
625
15.950
Why?
Carcinoma, Non-Small-Cell Lung
118
2021
316
15.650
Why?
Antineoplastic Combined Chemotherapy Protocols
74
2020
290
8.290
Why?
Antineoplastic Agents
40
2013
218
5.630
Why?
ErbB Receptors
23
2018
72
2.980
Why?
Quinazolines
10
2012
24
2.100
Why?
Carcinoma, Squamous Cell
23
2018
178
2.100
Why?
Paclitaxel
25
2015
74
1.970
Why?
Clinical Trials as Topic
22
2020
324
1.820
Why?
Biomarkers, Tumor
15
2021
175
1.820
Why?
Neoplasm Staging
51
2021
340
1.700
Why?
Neoplasm Recurrence, Local
19
2019
184
1.600
Why?
Cisplatin
38
2016
91
1.540
Why?
Humans
205
2021
29361
1.520
Why?
Carboplatin
23
2015
49
1.330
Why?
Adenocarcinoma
20
2018
189
1.310
Why?
Antibodies, Monoclonal, Humanized
16
2019
113
1.170
Why?
Prognosis
35
2021
840
1.170
Why?
Bevacizumab
10
2016
27
1.160
Why?
Middle Aged
106
2020
9823
1.150
Why?
Aged
99
2019
9447
1.110
Why?
Female
118
2020
16211
1.110
Why?
Pemetrexed
10
2016
14
1.070
Why?
Weight Gain
3
2016
66
1.060
Why?
Treatment Outcome
41
2021
3476
1.050
Why?
Disease-Free Survival
22
2018
175
1.020
Why?
Clinical Trials, Phase III as Topic
10
2016
23
1.020
Why?
Male
106
2019
15637
1.010
Why?
Survival Rate
32
2019
349
0.950
Why?
Taxoids
6
2008
14
0.940
Why?
Etoposide
22
2015
48
0.920
Why?
Protein Kinase Inhibitors
5
2020
47
0.910
Why?
Antibodies, Monoclonal
11
2016
260
0.900
Why?
Antineoplastic Agents, Phytogenic
9
2008
19
0.880
Why?
Eligibility Determination
2
2020
5
0.840
Why?
Adult
76
2019
8604
0.840
Why?
Apoptosis
12
2009
251
0.830
Why?
Survival Analysis
21
2021
298
0.800
Why?
Chemoradiotherapy
4
2015
67
0.770
Why?
Proteomics
3
2020
91
0.770
Why?
Drug Administration Schedule
20
2015
223
0.770
Why?
Adverse Drug Reaction Reporting Systems
1
2020
6
0.750
Why?
Patient Selection
8
2021
232
0.740
Why?
Combined Modality Therapy
31
2011
364
0.740
Why?
Mutation
11
2018
383
0.730
Why?
Ecosystem
1
2020
27
0.720
Why?
Quality of Life
11
2016
664
0.700
Why?
Carcinoma, Small Cell
12
2009
71
0.700
Why?
Drug Resistance, Neoplasm
10
2019
75
0.690
Why?
Small Cell Lung Carcinoma
5
2018
11
0.690
Why?
Gene Dosage
3
2018
23
0.690
Why?
Antineoplastic Agents, Immunological
4
2021
18
0.660
Why?
Molecular Targeted Therapy
3
2018
32
0.570
Why?
Carcinoma, Large Cell
5
2018
15
0.560
Why?
Aged, 80 and over
33
2018
4851
0.530
Why?
Immunotherapy
4
2021
62
0.520
Why?
PTEN Phosphohydrolase
2
2011
10
0.510
Why?
Disease Progression
15
2014
788
0.510
Why?
Kidney Neoplasms
3
2019
60
0.500
Why?
Randomized Controlled Trials as Topic
10
2018
340
0.480
Why?
Neoplasms
9
2011
247
0.480
Why?
Polyglutamic Acid
3
2008
4
0.480
Why?
Follow-Up Studies
15
2019
1829
0.470
Why?
Retrospective Studies
22
2018
3273
0.450
Why?
Carcinoma, Renal Cell
2
2019
35
0.450
Why?
Signal Transduction
5
2013
483
0.450
Why?
Kaplan-Meier Estimate
9
2018
162
0.450
Why?
Erlotinib Hydrochloride
6
2018
16
0.440
Why?
Guanine
7
2015
11
0.440
Why?
Glutamates
7
2015
17
0.430
Why?
Receptor, IGF Type 1
1
2012
18
0.430
Why?
Phosphatidylinositol 3-Kinases
1
2011
48
0.410
Why?
Megestrol
12
1996
12
0.370
Why?
Autoantibodies
3
2021
100
0.370
Why?
Radiotherapy
6
2009
50
0.360
Why?
Fluorouracil
12
2000
75
0.350
Why?
Neovascularization, Pathologic
3
2014
56
0.350
Why?
Cetuximab
4
2013
8
0.340
Why?
Breast Neoplasms
15
1998
329
0.340
Why?
Vinblastine
6
2009
8
0.330
Why?
Drug Delivery Systems
2
2010
37
0.320
Why?
Cyclooxygenase 2
1
2008
30
0.320
Why?
Uterine Cervical Neoplasms
7
1990
51
0.320
Why?
Gastrointestinal Hemorrhage
1
2008
22
0.320
Why?
Carcinoma, Bronchogenic
6
1988
11
0.320
Why?
Morpholines
1
2007
14
0.310
Why?
Protein-Tyrosine Kinases
2
2007
21
0.310
Why?
Neoplasm Metastasis
14
2014
101
0.310
Why?
Chromosomes, Human, Pair 7
1
2007
7
0.310
Why?
Macromolecular Substances
1
2007
17
0.300
Why?
Pneumonectomy
6
2012
67
0.300
Why?
Lipoxygenase Inhibitors
7
2003
13
0.290
Why?
Postoperative Complications
6
2019
957
0.280
Why?
Sulfonamides
3
2012
54
0.280
Why?
Adjuvants, Pharmaceutic
1
2005
2
0.280
Why?
Enzyme Inhibitors
3
2004
145
0.270
Why?
Melanoma
1
2006
52
0.270
Why?
Receptors, Progesterone
10
1988
27
0.270
Why?
Lung
4
2018
154
0.260
Why?
Aniline Compounds
3
2012
41
0.260
Why?
Indoles
8
2003
48
0.260
Why?
Proto-Oncogene Proteins c-bcl-2
5
2012
28
0.250
Why?
United States Food and Drug Administration
2
2020
70
0.250
Why?
Receptors, Estrogen
9
1988
58
0.240
Why?
Proportional Hazards Models
6
2013
340
0.230
Why?
United States
6
2020
2332
0.230
Why?
Antimetabolites, Antineoplastic
2
2000
26
0.230
Why?
Biomarkers
4
2018
692
0.220
Why?
Remission Induction
8
2010
96
0.220
Why?
Angiogenesis Inhibitors
2
2018
16
0.220
Why?
Matrix Metalloproteinase Inhibitors
1
2002
8
0.210
Why?
Matrix Metalloproteinases
1
2002
22
0.210
Why?
Gene Expression Regulation, Neoplastic
3
2018
100
0.200
Why?
Camptothecin
1
2001
3
0.200
Why?
Immunohistochemistry
4
2012
391
0.200
Why?
Thymoma
4
1996
13
0.190
Why?
Thymus Neoplasms
4
1996
12
0.190
Why?
Mediastinal Neoplasms
2
1991
12
0.190
Why?
Deoxycytidine
4
2016
31
0.190
Why?
DNA Methylation
2
2012
124
0.190
Why?
Lymphatic Metastasis
7
2010
81
0.190
Why?
Esophageal Neoplasms
2
2019
45
0.190
Why?
Neoadjuvant Therapy
2
2011
53
0.190
Why?
Stakeholder Participation
1
2020
9
0.190
Why?
Diarrhea
3
2007
48
0.180
Why?
Research Personnel
1
2020
20
0.180
Why?
Receptor, Adenosine A2A
1
2019
3
0.180
Why?
Clinical Trials, Phase II as Topic
4
2009
25
0.180
Why?
Drug Evaluation
11
1992
52
0.180
Why?
Proto-Oncogene Proteins
2
2016
31
0.180
Why?
Salvage Therapy
1
2019
36
0.180
Why?
Esophagectomy
1
2019
21
0.180
Why?
Regression Analysis
5
2009
298
0.180
Why?
Sarcopenia
1
2019
26
0.170
Why?
Receptor, ErbB-2
1
2018
41
0.160
Why?
Vascular Endothelial Growth Factor A
2
2008
65
0.160
Why?
Apoptosis Regulatory Proteins
2
2010
16
0.160
Why?
Syndecan-1
1
2018
8
0.160
Why?
Immunoassay
1
2018
43
0.160
Why?
Risk Assessment
5
2011
678
0.150
Why?
Nerve Growth Factors
1
2018
44
0.150
Why?
Inflammation Mediators
1
2018
83
0.150
Why?
Models, Statistical
1
1998
132
0.150
Why?
Pteridines
1
2016
1
0.150
Why?
Lung Diseases
1
1997
46
0.150
Why?
Tumor Cells, Cultured
9
2003
145
0.150
Why?
Cell Cycle Proteins
1
2016
17
0.150
Why?
Myasthenia Gravis
1
2017
11
0.150
Why?
Class I Phosphatidylinositol 3-Kinases
2
2018
12
0.150
Why?
Cell Division
9
2003
114
0.150
Why?
Palliative Care
2
2015
145
0.140
Why?
Genes, bcl-2
2
2011
3
0.140
Why?
Drug Discovery
1
2016
20
0.140
Why?
Muscle, Skeletal
1
2019
349
0.140
Why?
Cachexia
1
2016
11
0.140
Why?
Radiotherapy Dosage
7
2014
113
0.140
Why?
Exanthema
2
2007
15
0.140
Why?
Cohort Studies
8
2015
1939
0.130
Why?
Cyclin-Dependent Kinase Inhibitor p16
2
2012
22
0.130
Why?
Prostatic Neoplasms
5
1996
106
0.130
Why?
Interleukin-2
2
2009
66
0.130
Why?
Administration, Oral
5
2011
140
0.130
Why?
Isoxazoles
1
1994
16
0.120
Why?
Cell Survival
5
2013
169
0.120
Why?
Predictive Value of Tests
4
2009
521
0.120
Why?
Radiotherapy, Conformal
1
2014
19
0.120
Why?
src-Family Kinases
1
2013
8
0.120
Why?
Body Mass Index
1
2016
427
0.120
Why?
Genes, p16
1
2012
4
0.110
Why?
Triazoles
1
2013
30
0.110
Why?
Thrombocytopenia
2
2012
30
0.110
Why?
Vinca Alkaloids
1
2012
1
0.110
Why?
Folate Receptor 1
1
2012
1
0.110
Why?
Early Detection of Cancer
2
2010
79
0.110
Why?
Folic Acid
1
2012
16
0.110
Why?
Nogalamycin
1
1992
1
0.110
Why?
Young Adult
3
2014
1935
0.110
Why?
Platinum Compounds
2
2007
2
0.110
Why?
Area Under Curve
2
2009
66
0.110
Why?
Infusions, Intravenous
7
2006
76
0.110
Why?
Adolescent
3
2014
2280
0.110
Why?
Radiation Injuries
3
2015
34
0.110
Why?
Pyrimidines
2
2019
21
0.100
Why?
C-Peptide
1
2011
7
0.100
Why?
Insulin-Like Growth Factor Binding Proteins
1
2011
11
0.100
Why?
Cell Death
3
2003
61
0.100
Why?
Animals
8
2010
4577
0.100
Why?
Multicenter Studies as Topic
3
2002
75
0.100
Why?
Research Design
4
2016
212
0.100
Why?
Neoplasms, Germ Cell and Embryonal
1
1991
8
0.100
Why?
Insulin-Like Growth Factor I
1
2011
54
0.100
Why?
In Situ Hybridization, Fluorescence
2
2010
29
0.100
Why?
Gene Amplification
1
2010
19
0.100
Why?
Blood Chemical Analysis
1
2010
13
0.100
Why?
Hematologic Tests
1
2010
6
0.090
Why?
Protein Array Analysis
1
2010
10
0.090
Why?
Xanthine Dehydrogenase
1
2010
6
0.090
Why?
Calcium-Calmodulin-Dependent Protein Kinases
1
2010
21
0.090
Why?
Leukocyte Count
4
2017
92
0.090
Why?
Tumor Suppressor Proteins
1
2010
33
0.090
Why?
Inhibitor of Apoptosis Proteins
1
2009
4
0.090
Why?
Microtubule-Associated Proteins
1
2009
21
0.090
Why?
Radiotherapy Planning, Computer-Assisted
2
2014
67
0.090
Why?
Diphtheria Toxin
1
2009
2
0.090
Why?
Treatment Failure
3
2016
159
0.090
Why?
Neutropenia
1
2009
21
0.090
Why?
Colonic Neoplasms
7
1988
66
0.090
Why?
Smoking
3
2016
194
0.090
Why?
Pancreatic Neoplasms
4
2003
142
0.090
Why?
Forecasting
2
2001
117
0.090
Why?
B7-H1 Antigen
2
2021
13
0.090
Why?
Cyclophosphamide
6
1996
55
0.080
Why?
Organoplatinum Compounds
3
2002
7
0.080
Why?
Fatigue
1
2009
59
0.080
Why?
Piperidines
1
2008
32
0.080
Why?
Lymph Nodes
1
2009
70
0.080
Why?
Interferon Type I
2
1986
18
0.080
Why?
Logistic Models
2
2007
407
0.080
Why?
Celecoxib
1
2008
5
0.080
Why?
Peptic Ulcer
1
2008
6
0.080
Why?
Megestrol Acetate
9
1988
9
0.080
Why?
In Situ Hybridization
1
2008
46
0.080
Why?
Razoxane
1
1988
1
0.080
Why?
Receptors, Tumor Necrosis Factor
1
2008
33
0.080
Why?
Granulocyte Colony-Stimulating Factor
2
1998
12
0.080
Why?
Anemia
1
2009
97
0.080
Why?
Epothilones
1
2007
2
0.080
Why?
Drug Screening Assays, Antitumor
3
2003
14
0.080
Why?
Aneuploidy
1
2007
3
0.080
Why?
Pyrazoles
1
2008
44
0.080
Why?
Algorithms
4
2010
400
0.080
Why?
Tomography, X-Ray Computed
3
2014
770
0.080
Why?
Models, Theoretical
2
2005
91
0.080
Why?
DNA Mutational Analysis
1
2007
56
0.080
Why?
Piperazines
1
1988
90
0.070
Why?
Dactinomycin
2
2003
7
0.070
Why?
Carcinoma
3
1996
57
0.070
Why?
Time Factors
4
2018
1618
0.070
Why?
Radiotherapy, Adjuvant
2
2011
62
0.070
Why?
Polymerase Chain Reaction
1
2007
161
0.070
Why?
Antigens, Neoplasm
2
2021
37
0.070
Why?
Analysis of Variance
4
2011
321
0.070
Why?
Doxorubicin
6
1996
45
0.070
Why?
Endpoint Determination
1
2006
28
0.070
Why?
Proteasome Inhibitors
1
2005
3
0.070
Why?
Boronic Acids
1
2005
4
0.070
Why?
Bortezomib
1
2005
5
0.070
Why?
Pyrazines
1
2005
10
0.070
Why?
Drug Approval
1
2006
30
0.070
Why?
TNF-Related Apoptosis-Inducing Ligand
1
2005
8
0.070
Why?
Ligands
1
2005
55
0.070
Why?
Dose-Response Relationship, Drug
4
2011
437
0.070
Why?
Cause of Death
2
2009
65
0.070
Why?
Multivariate Analysis
4
2011
324
0.070
Why?
Cyclooxygenase Inhibitors
1
2005
36
0.070
Why?
Pilot Projects
5
2000
394
0.070
Why?
Membrane Glycoproteins
1
2005
101
0.070
Why?
Chemotherapy, Adjuvant
3
2011
75
0.060
Why?
Positron-Emission Tomography
1
2005
88
0.060
Why?
Tamoxifen
5
1988
30
0.060
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2005
107
0.060
Why?
Radiographic Image Interpretation, Computer-Assisted
1
2004
27
0.060
Why?
Tumor Necrosis Factor-alpha
1
2005
215
0.060
Why?
Cell Line, Tumor
3
2013
265
0.060
Why?
Prospective Studies
4
2018
1812
0.060
Why?
Radiometry
1
2004
38
0.060
Why?
Hematologic Diseases
2
2002
14
0.060
Why?
Digestive System Neoplasms
1
1984
5
0.060
Why?
Prostate
3
1997
33
0.060
Why?
Protein Synthesis Inhibitors
1
2003
9
0.060
Why?
Aminoquinolines
1
2003
1
0.060
Why?
Organic Chemicals
1
2003
8
0.060
Why?
Recurrence
2
2016
350
0.060
Why?
Pyrroles
1
2003
17
0.060
Why?
Sensitivity and Specificity
4
2009
553
0.060
Why?
Epidermal Growth Factor
1
2003
29
0.060
Why?
Health Status Indicators
1
2004
78
0.060
Why?
Oligonucleotide Array Sequence Analysis
2
2002
58
0.060
Why?
Aminoacridines
1
1983
2
0.060
Why?
Pyridines
2
2019
42
0.060
Why?
Genetic Therapy
1
2004
89
0.060
Why?
Imaging, Three-Dimensional
1
2004
222
0.060
Why?
Antibiotics, Antineoplastic
2
2003
14
0.050
Why?
Injections, Intravenous
3
1999
56
0.050
Why?
Lymphocytes
2
2017
110
0.050
Why?
Image Processing, Computer-Assisted
2
2012
219
0.050
Why?
Neoplasm Invasiveness
1
2002
68
0.050
Why?
Radiation Pneumonitis
2
2015
4
0.050
Why?
Mitomycins
4
1989
4
0.050
Why?
Health Status
1
2003
227
0.050
Why?
Oxidative Stress
1
2002
124
0.050
Why?
Antineoplastic Agents, Alkylating
1
2001
4
0.050
Why?
Programmed Cell Death 1 Receptor
1
2021
18
0.050
Why?
Observer Variation
1
2021
118
0.050
Why?
Genome
1
2000
15
0.050
Why?
Adrenalectomy
1
2000
2
0.050
Why?
Tomography, Emission-Computed
1
2000
11
0.050
Why?
Adrenal Gland Neoplasms
1
2000
11
0.050
Why?
Dyspnea
2
2015
37
0.050
Why?
Maximum Tolerated Dose
2
2011
16
0.050
Why?
DNA Damage
3
2008
30
0.050
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
1997
9
0.050
Why?
Furans
1
2019
3
0.050
Why?
Genes, Tumor Suppressor
1
1999
12
0.040
Why?
Interferon-beta
1
1999
7
0.040
Why?
Oncogenes
1
1999
13
0.040
Why?
Methotrexate
3
1989
41
0.040
Why?
Retinoblastoma Binding Proteins
1
2018
1
0.040
Why?
Platelet Count
3
1989
20
0.040
Why?
Free Radical Scavengers
1
1999
12
0.040
Why?
North America
1
2018
38
0.040
Why?
Neoplasm Grading
1
2018
45
0.040
Why?
Ubiquitin-Protein Ligases
1
2018
36
0.040
Why?
Liver Neoplasms
3
2005
103
0.040
Why?
Interferons
1
1998
13
0.040
Why?
Case-Control Studies
2
2010
638
0.040
Why?
Random Allocation
4
1986
146
0.040
Why?
Neoplasms, Hormone-Dependent
3
1986
5
0.040
Why?
Echinomycin
1
1998
1
0.040
Why?
Trimetrexate
1
1998
1
0.040
Why?
DNA, Neoplasm
2
1996
25
0.040
Why?
Tumor Suppressor Protein p53
1
2018
89
0.040
Why?
Cell Differentiation
2
1996
146
0.040
Why?
Phenotype
1
2018
357
0.040
Why?
Age Factors
3
2012
845
0.040
Why?
Agranulocytosis
1
1996
5
0.040
Why?
Administration, Intravenous
1
2016
29
0.040
Why?
Fadrozole
1
1996
1
0.040
Why?
Body Weight
1
2017
133
0.040
Why?
Surveys and Questionnaires
1
2002
1184
0.040
Why?
Genetic Predisposition to Disease
1
2018
441
0.040
Why?
Cell Transformation, Neoplastic
1
1996
34
0.040
Why?
Neutrophils
1
2017
117
0.040
Why?
Flow Cytometry
3
2003
199
0.040
Why?
Longitudinal Studies
2
1998
1442
0.030
Why?
Stem Cells
1
1996
46
0.030
Why?
Hemoptysis
1
2015
8
0.030
Why?
Pneumonia
1
1996
67
0.030
Why?
Esophagitis
1
2015
11
0.030
Why?
Cough
1
2015
12
0.030
Why?
Chemoradiotherapy, Adjuvant
1
2015
16
0.030
Why?
Chest Pain
1
2015
24
0.030
Why?
Calcium
2
1997
495
0.030
Why?
Drug Tolerance
1
1995
12
0.030
Why?
Thorax
1
1995
12
0.030
Why?
Teniposide
1
1995
2
0.030
Why?
Gallium
1
1995
4
0.030
Why?
Imides
1
1995
2
0.030
Why?
Isoquinolines
1
1995
14
0.030
Why?
Drugs, Investigational
1
1995
8
0.030
Why?
DNA Repair
2
2008
7
0.030
Why?
Feasibility Studies
1
1995
227
0.030
Why?
Vincristine
2
1992
26
0.030
Why?
Drug Resistance
1
1994
55
0.030
Why?
Comorbidity
1
2016
497
0.030
Why?
Optics and Photonics
1
1994
2
0.030
Why?
S Phase
1
1994
10
0.030
Why?
Mobility Limitation
1
2015
97
0.030
Why?
Reactive Oxygen Species
1
1994
126
0.030
Why?
Cell Nucleus
1
1994
79
0.030
Why?
Proto-Oncogene Proteins c-met
1
2013
4
0.030
Why?
Protein Kinase C beta
1
2013
7
0.030
Why?
Proteins
2
1985
73
0.030
Why?
Diet
1
2015
174
0.030
Why?
Receptor Protein-Tyrosine Kinases
1
2013
7
0.030
Why?
Gene Rearrangement
1
2013
10
0.030
Why?
HSP90 Heat-Shock Proteins
1
2013
7
0.030
Why?
Protein Kinase C
1
2013
44
0.030
Why?
Enzyme Activation
1
2013
109
0.030
Why?
Protein Binding
1
2013
127
0.030
Why?
Biopsy
1
1994
234
0.030
Why?
Phosphorylation
1
2013
159
0.030
Why?
Procarbazine
2
1989
3
0.030
Why?
Radiography, Thoracic
1
2012
28
0.030
Why?
Cell Membrane
1
2013
105
0.030
Why?
Oligopeptides
1
2012
30
0.030
Why?
Menogaril
1
1992
1
0.030
Why?
Drug Therapy, Combination
3
1999
241
0.030
Why?
Child, Preschool
1
1994
641
0.030
Why?
Epigenesis, Genetic
1
2012
74
0.030
Why?
Illinois
1
2012
241
0.030
Why?
Genotype
1
2013
405
0.030
Why?
Preoperative Care
2
2009
135
0.030
Why?
Activities of Daily Living
1
2015
502
0.030
Why?
Rectal Neoplasms
2
1988
19
0.020
Why?
Misonidazole
1
1990
2
0.020
Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
9
0.020
Why?
Serum
1
2010
9
0.020
Why?
Tandem Mass Spectrometry
1
2010
26
0.020
Why?
Antibodies, Neoplasm
1
2010
10
0.020
Why?
DNA Modification Methylases
1
2010
3
0.020
Why?
Death-Associated Protein Kinases
1
2010
4
0.020
Why?
DNA Repair Enzymes
1
2010
6
0.020
Why?
Monomeric GTP-Binding Proteins
1
2010
6
0.020
Why?
Immunoenzyme Techniques
1
2010
40
0.020
Why?
CpG Islands
1
2010
34
0.020
Why?
Cadherins
1
2010
31
0.020
Why?
Neoplasm Proteins
1
2010
50
0.020
Why?
Promoter Regions, Genetic
1
2010
80
0.020
Why?
Antigens, CD
1
2010
99
0.020
Why?
Adaptor Proteins, Signal Transducing
1
2010
76
0.020
Why?
Lymph Node Excision
1
2009
26
0.020
Why?
Drug Synergism
1
1989
63
0.020
Why?
Soft Tissue Neoplasms
2
1988
24
0.020
Why?
Recombinant Fusion Proteins
1
2009
29
0.020
Why?
Vindesine
2
1986
3
0.020
Why?
Nervous System Neoplasms
1
1988
3
0.020
Why?
Endocrine System Diseases
1
1988
3
0.020
Why?
California
1
2008
31
0.020
Why?
Electrophoresis, Polyacrylamide Gel
2
1985
38
0.020
Why?
Molecular Weight
2
1985
45
0.020
Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
1
2008
1
0.020
Why?
Creatine Kinase
1
1988
33
0.020
Why?
Adenocarcinoma, Bronchiolo-Alveolar
1
2007
3
0.020
Why?
Bone Neoplasms
2
1988
102
0.020
Why?
Piroxicam
1
1987
5
0.020
Why?
Receptors, Steroid
1
1987
3
0.020
Why?
Altretamine
1
1986
1
0.020
Why?
Receptors, Cell Surface
1
1986
50
0.020
Why?
Radiation Protection
1
2005
5
0.020
Why?
Menopause
3
1996
134
0.020
Why?
Head and Neck Neoplasms
2
1984
133
0.020
Why?
Models, Biological
2
1999
344
0.020
Why?
Radiopharmaceuticals
1
2005
48
0.020
Why?
Fluorodeoxyglucose F18
1
2005
39
0.020
Why?
Sarcoma
1
1986
65
0.020
Why?
Rosaniline Dyes
1
1985
1
0.020
Why?
Nomograms
1
2005
5
0.020
Why?
Prostatic Hyperplasia
1
1985
17
0.020
Why?
Relative Biological Effectiveness
1
2004
5
0.020
Why?
Body Burden
1
2004
9
0.020
Why?
Radiation Dosage
1
2004
31
0.020
Why?
Bone Marrow
1
1985
76
0.020
Why?
Skin Neoplasms
1
2005
65
0.020
Why?
Hepatectomy
1
1984
55
0.010
Why?
Women's Health
1
2006
245
0.010
Why?
Nucleosomes
1
2003
3
0.010
Why?
DNA Fragmentation
1
2003
7
0.010
Why?
Tumor Stem Cell Assay
1
2003
6
0.010
Why?
Stomach Neoplasms
1
1984
30
0.010
Why?
Caspases
1
2003
32
0.010
Why?
Cell Culture Techniques
1
2003
44
0.010
Why?
Molybdenum
2
1980
22
0.010
Why?
Cytosol
2
1980
62
0.010
Why?
Amsacrine
1
1983
2
0.010
Why?
Sleep Stages
1
2002
34
0.010
Why?
Carcinoma, Hepatocellular
1
1983
32
0.010
Why?
Reproducibility of Results
1
2004
788
0.010
Why?
Blood Platelets
1
1982
49
0.010
Why?
Paraneoplastic Endocrine Syndromes
1
1981
2
0.010
Why?
Spin Labels
1
2001
2
0.010
Why?
Nitrogen Oxides
1
2001
2
0.010
Why?
Cyclic N-Oxides
1
2001
5
0.010
Why?
Carcinoma, Intraductal, Noninfiltrating
1
1981
8
0.010
Why?
Amides
1
2001
21
0.010
Why?
Apudoma
1
1981
2
0.010
Why?
Psychometrics
1
2002
262
0.010
Why?
DNA Replication
1
2000
12
0.010
Why?
Dexamethasone
1
2000
48
0.010
Why?
Genes, cdc
1
1999
1
0.010
Why?
Ribonucleases
1
1999
9
0.010
Why?
DNA, Complementary
1
1999
28
0.010
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
1999
145
0.010
Why?
Blotting, Western
1
1999
170
0.010
Why?
Free Radicals
1
1999
9
0.010
Why?
Hematopoiesis
1
1999
11
0.010
Why?
Reperfusion Injury
1
1999
8
0.010
Why?
Demography
1
1999
77
0.010
Why?
Myelodysplastic Syndromes
1
1999
35
0.010
Why?
RNA, Messenger
1
1999
323
0.010
Why?
Intercalating Agents
1
1998
1
0.010
Why?
Risk Factors
1
2004
2446
0.010
Why?
Amiloride
1
1997
5
0.010
Why?
Fura-2
1
1997
4
0.010
Why?
Fluoresceins
1
1997
8
0.010
Why?
Trypsin
1
1997
6
0.010
Why?
Dimethyl Sulfoxide
1
1996
3
0.010
Why?
DNA
1
1997
125
0.010
Why?
Mitosis
1
1996
9
0.010
Why?
G2 Phase
1
1996
4
0.010
Why?
Fatal Outcome
1
1996
59
0.010
Why?
Hydrogen-Ion Concentration
1
1997
148
0.010
Why?
Prostaglandins
1
1996
4
0.010
Why?
Genes, Homeobox
1
1996
5
0.010
Why?
Telomerase
1
1996
9
0.010
Why?
Postoperative Care
1
1997
127
0.010
Why?
Inflammation
1
1999
345
0.010
Why?
Cell Count
1
1996
99
0.010
Why?
Biological Evolution
1
1996
23
0.010
Why?
Ifosfamide
1
1995
8
0.010
Why?
Progesterone
2
1988
26
0.010
Why?
Naphthalimides
1
1995
2
0.010
Why?
Adenine
1
1995
5
0.010
Why?
Organophosphonates
1
1995
5
0.010
Why?
Double-Blind Method
1
1996
503
0.010
Why?
Isoelectric Focusing
2
1985
4
0.010
Why?
HIV Infections
1
1999
980
0.010
Why?
Radiation-Sensitizing Agents
1
1990
10
0.010
Why?
Microscopy, Electron
1
1988
70
0.010
Why?
Mitomycin
1
1988
12
0.010
Why?
Patient Participation
1
1988
52
0.010
Why?
Isoenzymes
1
1988
50
0.010
Why?
Axilla
1
1987
11
0.000
Why?
Killer Cells, Natural
1
1987
91
0.000
Why?
Colon
1
1988
148
0.000
Why?
Monocytes
1
1987
116
0.000
Why?
Lymphocyte Activation
1
1987
209
0.000
Why?
Indicators and Reagents
1
1985
14
0.000
Why?
Actuarial Analysis
1
1984
14
0.000
Why?
Risk
1
1984
217
0.000
Why?
Electrophoresis
1
1983
15
0.000
Why?
Radiography
1
1985
678
0.000
Why?
Maytansine
1
1982
3
0.000
Why?
Streptozocin
1
1982
6
0.000
Why?
Carcinoembryonic Antigen
1
1982
6
0.000
Why?
Leukopenia
1
1982
8
0.000
Why?
Cytoplasmic Granules
1
1981
9
0.000
Why?
Castration
1
1981
4
0.000
Why?
Pelvic Neoplasms
1
1981
7
0.000
Why?
Charcoal
1
1980
2
0.000
Why?
Dextrans
1
1980
5
0.000
Why?
Centrifugation, Density Gradient
1
1980
13
0.000
Why?
Tritium
1
1980
14
0.000
Why?
Uterus
1
1980
15
0.000
Why?
Brain Neoplasms
1
1981
124
0.000
Why?
In Vitro Techniques
1
1980
213
0.000
Why?
Bonomi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (526)
Explore
_
Co-Authors (14)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_